on Onco-Innovations Limited (CVE:ONCO)
Onco-Innovations CEO Discusses Breakthroughs in Cancer Treatment on Popular Program
Onco-Innovations Limited, noted for its focus on oncology, recently had its CEO, Thomas O'Shaughnessy, featured on Conversations That Matter. In the interview, O'Shaughnessy shared insights into the company's progress in developing treatments for colorectal cancer and other tumours. The broadcast, seen in various Canadian media, underscored Onco's commitment to precision medicine and innovative cancer therapies.
Key topics included the integration of artificial intelligence via their Inka Health AI acquisition and partnerships with prominent research organizations and big-pharma like AstraZeneca Canada. These collaborations aim to advance precision medicine in cancer treatment. O'Shaughnessy emphasized Onco-Innovations' commitment to accelerating clinical trials and achieving global impact in cancer treatment.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Onco-Innovations Limited news